direct
mechan
action
antivir
mab
mab
therapi
form
passiv
immunotherapi
see
glossari
classic
intend
blunt
viral
infect
via
direct
rapid
target
infecti
agent
rather
via
trigger
longterm
immun
respons
therapeut
approach
contrast
vaccin
approach
aim
stimul
endogen
immun
respons
host
order
provid
sustain
protect
immun
mab
diminish
viral
dissemin
direct
action
involv
antigenbind
activ
effector
function
born
fc
fragment
far
antivir
mab
therapeut
potenti
initi
logic
select
abil
neutral
virion
via
recognit
viral
surfac
antigen
essenti
receptor
bind
andor
entri
host
trend
antivir
monoclon
antibodi
mab
promis
highaddedvalu
biotherapeut
recent
year
number
antivir
mab
develop
acut
chronic
virus
grown
exponenti
current
test
clinic
trial
antivir
mab
use
blunt
viral
propag
direct
effect
also
engag
host
immun
system
lead
induct
longlast
protect
vaccinelik
effect
assess
mechan
play
induct
vaccinelik
effect
antivir
mab
help
improv
antivir
treatment
exploit
effect
translat
therapeut
benefit
patient
benefit
also
help
healthcar
system
reduct
treatment
cost
cell
furthermor
direct
recognit
also
shown
inhibit
cellcel
transmiss
virion
certain
set
antivir
mab
studi
date
immunoglobulin
gs
igg
antibodi
effici
recogn
complement
fcg
receptor
fcgr
born
mani
cell
immun
system
addit
complementmedi
inactiv
viral
particl
andor
phagocytosi
also
permit
complementdepend
cytotox
cdc
antibodydepend
cellular
phagocytosi
adcp
antibodydepend
cellmedi
cytotox
adcc
elimin
infect
cell
display
viral
antigen
surfac
figur
instanc
case
mab
target
envelop
glycoprotein
env
hiv
lentiretrovirus
expos
surfac
virusproduc
cell
final
fcfcgr
interact
also
directli
impact
viral
propag
via
mechan
call
antibodydepend
cellmedi
viru
inhibit
adcvi
see
inform
direct
fcmediat
antivir
effect
thu
immunotherapi
mab
impact
viral
propag
via
varieti
direct
mechan
possibl
vari
accord
viru
viral
antigen
recogn
antibodi
howev
accumul
evid
antivir
mab
upon
interact
differ
compon
immun
system
also
oper
via
indirect
mechan
engag
host
immun
respons
effect
last
well
beyond
treatment
thu
similarli
vaccin
approach
mab
treatment
could
lead
stimul
endogen
humor
cellular
immun
respons
manner
provid
protect
immun
vaccinelik
effect
antibodydepend
cellmedi
cytotox
adcc
mechan
cellmedi
immun
wherebi
effector
cell
immun
system
lyse
target
cell
bound
specif
antibodi
fc
portion
coat
antibodi
interact
fc
receptor
express
immun
effector
cell
mainli
natur
killer
cell
nk
therebi
initi
signal
cascad
result
releas
cytotox
granul
induc
death
antibodyco
cell
antibodydepend
cellular
phagocytosi
adcp
mechan
cellmedi
immun
wherebi
cell
immun
system
phagocytos
target
cell
bound
specif
antibodi
similar
adcc
fc
portion
coat
antibodi
interact
fc
receptor
express
phagocyt
ie
macrophag
granulocyt
dendrit
cell
antibodydepend
cellmedi
viru
inhibit
adcvi
mechan
antibodymedi
immun
wherey
infect
target
cell
interact
effector
cell
express
one
sever
fcgr
via
viralspecif
antibodi
adcvi
measur
impact
antibodi
fcgrbear
effector
cell
viru
output
infect
target
cell
includ
lytic
ie
adcc
nonlyt
ie
product
chemokin
mechan
lead
decreas
viral
spread
complementdepend
cytotox
cdc
mechan
antibodymedi
immun
wherebi
antibodi
bind
complement
compon
activ
classic
complement
cascad
lead
format
membran
attack
complex
cytolyt
end
product
complement
cascad
lysi
cell
target
antibodi
fab
fragment
region
antibodi
bind
antigen
compos
one
constant
one
variabl
domain
heavi
light
chain
vh
vl
respect
f
ab
two
fab
fragment
link
short
fragment
constant
part
antibodi
hing
region
affin
whole
antibodi
dival
immunotherapi
period
antivir
mab
form
immun
complex
ic
virion
case
infect
cell
ic
recogn
antigenpres
cell
apc
dendrit
cell
dc
central
adapt
immun
respons
figur
surprisingli
recent
scientif
medic
commun
larg
fail
take
consider
could
impact
endogen
immun
ie
enhanc
antibodi
respons
well
cytotox
tcell
respons
infect
immunotherapytr
patient
puzzl
posit
immunomodulatori
vaccinelik
effect
strengthen
patient
immun
defens
viral
infect
would
translat
obviou
benefit
patient
also
healthcar
system
would
benefit
reduc
cost
durat
treatment
sever
object
reason
might
explain
situat
first
antivir
mab
initi
select
basi
blunt
effect
viral
propag
second
model
viral
infect
immunocompet
anim
allow
indepth
analys
endogen
immun
respons
context
passiv
mabbas
immunotherapi
scarc
especi
true
relev
model
chronic
infect
virus
hiv
hcv
antivir
mab
avail
date
rais
inde
antihiv
lesser
extent
antihcv
mab
activ
assess
mainli
immunocomprom
human
mice
reconstitut
partial
human
immun
system
andor
nonhuman
primat
nhp
although
nhp
extrem
use
assess
protect
effect
antihiv
mab
use
studi
immun
limit
due
technic
cost
reason
contrast
mous
infect
system
offer
numer
immunolog
tool
permit
costeffect
experiment
larg
cohort
third
often
antivir
mab
gener
speci
differ
use
vivo
experi
therefor
fcassoci
effector
function
fulli
preserv
final
ethic
technic
econom
reason
togeth
low
number
ongo
clinic
trial
still
limit
type
investig
human
despit
appar
unfavor
context
howev
evid
gain
variou
anim
model
recent
demonstr
vaccinelik
effect
induc
short
mab
therapi
experi
review
potenti
improv
approach
discuss
frcase
retroviru
murin
leukemia
viru
mlv
frcase
infect
newborn
mice
reminisc
perinat
infect
hiv
viral
expans
occur
organ
develop
immun
provid
one
rare
model
chronic
viral
infect
immunocompet
anim
neutral
mab
speci
mous
avail
first
experiment
system
permit
unambigu
demonstr
possibl
induc
vaccinelik
effect
mabbas
immunotherapi
inocul
pup
frcase
induc
fatal
erythroleukemia
neurodegener
inocul
earlier
associ
weak
nonprotect
humor
cellular
antivir
immun
respons
howev
short
treatment
day
neutral
equival
human
mab
recogn
viral
env
shortli
infect
allow
infect
mice
surviv
good
health
normal
lifespan
surviv
associ
decreas
viral
propag
importantli
strictli
depend
develop
lifelong
protect
endogen
antivir
immun
respons
immun
type
humor
arm
direct
viru
cytotox
tcell
arm
direct
infectedleukem
cell
display
strong
memori
respons
challeng
experi
detail
analys
indic
induct
protect
immun
mere
result
reduct
viral
glycosyl
pattern
modifi
enhanc
effector
function
fc
fragment
fragment
crystalliz
region
fc
region
tail
region
antibodi
interact
cellsurfac
receptor
call
fc
receptor
protein
complement
system
properti
allow
antibodi
activ
immun
system
fc
receptor
fcr
receptor
fc
portion
immunoglobulin
constitut
famili
cellsurfac
molecul
express
mani
cell
immun
system
sever
differ
type
fcr
classifi
base
type
antibodi
recogn
exampl
bind
common
class
antibodi
igg
call
fcgamma
receptor
fcgr
immun
checkpoint
number
differ
inhibitori
pathway
immun
system
necessari
maintain
selftoler
modul
durat
magnitud
immun
respons
order
minim
collater
tissu
damag
mani
immun
checkpoint
involv
ligandreceptor
interact
cell
antigenpres
cell
ie
neonat
fcr
fcrn
fc
receptor
structual
relat
mhc
class
molecul
protect
igg
degrad
result
long
serum
halflif
addit
fcrn
mediat
igg
transfer
mother
fetu
therebi
provid
passiv
immun
passiv
immunotherapi
transfer
nonimmun
patient
activ
antibodi
immunesystem
compon
produc
outsid
bodi
ie
laboratori
isol
immun
donor
approach
help
combat
diseas
treatment
vaccin
avail
provid
shortterm
immun
regulatori
cell
treg
subpopul
cell
immunosuppress
activ
cell
observ
case
chronic
viral
infect
lead
dampen
antivir
immun
respons
vaccin
biolog
prepar
confer
protect
immun
specif
diseas
usual
employ
innocu
form
diseas
load
immunotherapi
consequ
genuin
immunomodulatori
action
therapeut
mab
involv
variou
fcgrdepend
mechan
particular
mab
induc
envexpress
infect
cell
lysi
natur
killer
nk
celldepend
adcc
mechan
like
provid
inflammatori
environ
favor
induct
antivir
immun
respons
moreov
ic
form
infect
cell
effici
captur
dc
infect
cell
alon
lead
stronger
function
dc
activ
elicit
potent
antivir
cytotox
lymphocyt
ctl
respons
figur
key
figur
importantli
endogen
antivir
antibodi
gener
immunotherapi
allow
contain
viral
propag
contribut
mainten
tcell
memori
respons
therapeut
antibodi
elimin
treat
mice
third
fcgrdepend
effect
describ
inhibit
expans
regulatori
cell
treg
essenti
induct
protect
immun
figur
find
fact
agent
kill
weaken
bacteria
virus
stimul
bodi
immun
system
recogn
agent
foreign
destroy
also
confer
immunolog
memori
agent
induct
surpris
treg
expans
associ
type
chronic
viral
infect
lead
dampen
antivir
immun
respons
promot
chronic
subsequ
patholog
manifest
thu
frcase
model
provid
proof
concept
short
mabbas
antivir
therapi
induc
lifelong
protect
immun
permit
infect
organ
surviv
good
health
yet
number
issu
still
pend
particular
crucial
identifi
cell
type
molecular
effector
involv
process
well
elucid
mechan
wherebi
longterm
immun
maintain
order
appli
treatment
human
diseas
mab
direct
human
virus
also
gener
vaccinelik
effect
antivir
immun
respons
induc
strengthen
antivir
mabbas
immunotherapi
also
observ
variou
chronic
acut
lifethreaten
human
virus
see
summari
tabl
notabl
preclin
nhp
model
hiv
infect
use
secondgener
broadli
neutral
antibodi
bnab
observ
import
mab
test
clinic
trial
simian
immunodefici
viru
siv
infect
macaqu
differ
strain
siv
wide
use
nhp
model
hiv
infect
well
immunotherapi
experi
sever
report
indic
short
treatment
sivinfect
macaqu
neutral
antibodi
lead
enhanc
antivir
immun
howev
experi
perform
sivspecif
highli
neutral
polyclon
immun
globulin
sivig
prepar
sivinfect
anim
mab
first
studi
sivig
treatment
could
significantli
delay
diseas
onset
increas
surviv
rate
macaca
mulatta
macaqu
longterm
survivor
show
acceler
de
novo
product
antisivneutr
antibodi
anoth
set
experi
rhesu
macaqu
treat
sivig
shortli
infect
result
transient
detect
neutralizingantibodi
respons
follow
reduct
viral
load
compar
untreat
macaqu
interestingli
virusspecif
polyfunct
tcell
respons
also
induc
acut
phase
infect
maintain
elev
follow
chronic
phase
togeth
tcell
antivir
respons
measur
appear
ctl
specif
capsid
gag
intriguingli
neutral
antibodi
could
measur
latter
phase
ie
sivig
disappear
underlin
strike
differ
mulata
macaqu
frcase
model
reason
elucid
moreov
dc
stimul
vitro
sivigpreincub
siv
shown
activ
virusspecif
lymphocyt
fcdepend
manner
suggest
enhanc
tcell
prime
immunotherapi
period
depend
antibodymedi
virion
uptak
apc
conclus
consist
former
observ
mhc
class
irestrict
crosspresent
siv
capsid
protein
gag
enhanc
antigag
antibodi
gener
stronger
gagspecif
tcell
respons
sivinfect
macaqu
thu
taken
togeth
experi
suggest
administr
neutral
antibodi
strengthen
antivir
immun
lentivirusinfect
organ
also
point
crucial
role
viral
ic
observ
effect
simian
hiv
shiv
simian
hiv
chimer
viru
hiv
env
substitut
siv
use
pertin
assess
effect
hivneutr
mab
nhp
interestingli
pigtail
macaqu
treat
human
hivneutr
mab
one
first
gener
combin
polyclon
shivig
oral
challeng
shiv
strain
develop
acceler
neutral
antibodi
respons
show
reduc
plasma
viremia
least
month
howev
infect
model
despit
high
persist
viremia
evid
pathogenesi
period
studi
preclud
assess
viral
diseas
protect
mabinduc
bcell
respons
contrast
studi
perform
use
oral
infect
rhesu
macaqu
viru
lead
diseas
manifest
within
week
model
passiv
immunotherapi
polyclon
shivig
h
prior
infect
reduc
viral
propag
acceler
de
novo
neutral
antibodi
product
also
translat
adcvi
associ
protect
diseas
data
consist
concept
protect
immunomodulatori
effect
induc
passiv
immunotherapi
neutral
antibodi
least
administ
time
infect
effect
howev
also
seem
possibl
upon
mab
treatment
much
later
time
exampl
administr
either
cocktail
mab
mab
alon
month
infect
rhesu
macaqu
result
rapid
declin
plasma
viremia
undetect
level
correl
slight
increas
neutral
antibodi
titer
interestingli
humor
respons
complement
tcell
respons
character
signific
improv
function
gagspecif
lymphocyt
manifest
decreas
express
exhaust
marker
despit
chang
number
moreov
viru
rebound
major
anim
serum
mab
disappear
subset
anim
maintain
longterm
virolog
control
absenc
mab
infus
overal
data
demonstr
strong
therapeut
effect
potent
neutral
mab
shivinfect
rhesu
monkey
well
posit
impact
immun
respons
find
potenti
import
recent
mab
shown
safe
effect
reduc
viremia
phase
human
clinic
trial
notion
neutral
mab
treatment
enhanc
antivir
immun
respons
support
experi
exampl
treat
straininfect
rhesu
macaqu
neutral
mab
led
undetect
viru
level
develop
gagspecif
respons
although
diseas
progress
assess
long
term
addit
singl
bnab
control
shiv
infect
immunecompet
macaqu
shivinfect
human
mice
suggest
macaqu
host
immun
respons
contribut
viremia
control
immunotherapi
success
prevent
resurg
bnab
escap
variant
thu
shiv
infect
model
strongli
suggest
neutral
antihiv
antibodi
therapi
may
least
certain
extent
recruit
infect
host
immun
system
gener
antivir
effect
import
issu
maxim
effect
effici
treatment
hivinfect
human
see
evid
neutral
mab
immunotherapi
affect
endogen
antivir
immun
respons
chronic
infect
also
acut
infect
exampl
prophylact
treatment
rsv
acut
cytopath
viru
neutral
mab
direct
toward
g
attach
protein
also
strong
immunosuppress
activ
shift
adapt
immun
respons
thu
mabtreat
mice
infect
rsv
strain
show
enhanc
sustain
humor
respons
character
increas
ratio
antirsv
compar
nontreat
infect
mice
moreov
stimul
skew
humor
respons
also
correl
increas
follicular
helper
cell
tfh
higher
frequenc
cell
direct
infect
cell
note
howev
effect
bcell
tcell
respons
fcdepend
f
ab
fragment
lead
shift
adapt
immun
respons
whole
mab
data
suggest
neutral
viru
via
target
one
immunosuppress
protein
may
repres
attract
approach
induc
protect
antivir
immun
hendra
nipah
henipavirus
hendra
hev
nipah
niv
relat
acut
fatal
henipavirus
therapeut
mab
also
develop
hev
challeng
african
green
monkey
mirror
fatal
human
infect
lead
death
day
postinfect
upon
rapid
infus
human
hevneutr
mab
infect
monkey
surviv
transient
display
neurolog
symptom
recoveri
diseas
correl
mount
protect
humor
immun
respons
reduc
viral
load
interestingli
mab
crossreact
niv
use
postexposur
therapi
nivinfect
african
green
monkey
also
lead
develop
antivir
humor
respons
like
limit
viral
dissemin
contribut
protect
niv
diseas
thu
crossreact
mab
current
develop
human
use
nipahand
hendraviru
countermeasur
show
except
efficaci
direct
antivir
action
probabl
also
abil
affect
endogen
immun
import
issu
translat
newli
establish
concept
vaccinelik
effect
antivir
mab
actual
effici
human
medic
applic
indepth
analysi
underli
cellular
molecular
mechan
play
experiment
set
alreadi
hand
whether
rodent
nhp
certainli
help
toward
aim
howev
three
obviou
line
immunotherapi
improv
alreadi
consid
figur
reason
suspect
combin
mab
treatment
therapi
may
strengthen
induc
antivir
vaccinelik
effect
first
approach
might
reli
inhibit
immunosuppressor
mechan
infect
treat
individu
exampl
via
depress
treg
treatment
entail
either
deplet
andor
loss
activ
review
would
pertin
treg
expans
dampen
antivir
immun
number
infect
see
target
immun
checkpoint
may
repres
anoth
option
could
achiev
use
mab
current
use
treat
cancer
review
fact
inhibit
interact
enhanc
virusspecif
cellular
immun
respons
differ
anim
model
hcv
hepat
b
viru
hbv
hiv
siv
murin
retroviru
infect
provid
support
idea
well
observ
blockad
stimul
antihbv
cellular
immun
hbvinfect
patient
associ
cure
small
subset
hcvinfect
patient
combin
antivir
mab
immunostimulatori
agent
also
consid
agonist
mab
target
tcell
costimulatori
receptor
gitr
review
current
test
clinic
may
serv
purpos
engag
costimulatori
receptor
alreadi
known
enhanc
antivir
cellular
immun
differ
infect
set
altern
agonist
tolllik
receptor
tlr
could
use
one
hand
activ
tlr
essenti
develop
mani
natur
antivir
respons
hand
agonist
alreadi
shown
cooper
enhanc
env
humor
respons
rhesu
macaqu
support
idea
come
observ
combin
antitumor
mab
differ
tlr
agonist
improv
sever
cancer
immunotherapi
lastli
combin
mab
therapi
latenc
revers
agent
flush
virus
reservoir
might
use
stimul
antihiv
immun
releas
viral
antigen
favor
format
ic
therebi
subsequ
stimul
apc
support
idea
possibl
cooper
two
therapeut
broadli
neutral
mab
alreadi
shown
capabl
cooper
sever
viral
induc
decreas
rebound
latent
reservoir
human
mice
vaccinelik
effect
howev
could
studi
case
fcborn
effector
function
known
essenti
antivir
protect
variou
mab
suggest
fc
engin
could
repres
avenu
improv
direct
mab
antivir
efficaci
also
induc
stronger
vaccinelik
effect
particular
enhanc
affin
mab
fcgr
display
apc
could
achiev
via
modif
fcgr
peptidebind
motif
via
product
mab
alter
glycosyl
enhanc
bind
fcgr
inde
fcengin
glycovari
shown
enhanc
fcmediat
reduct
viral
replic
fcgr
bind
differ
vitro
infect
set
ebola
viru
hiv
also
support
idea
spontan
control
hiv
improv
antivir
activ
correl
dramat
shift
global
antibodyglycosyl
profil
toward
agalactosyl
glycoform
anoth
interest
possibl
fc
engin
may
aim
enhanc
bind
neonat
fc
receptor
fcrn
express
variou
adult
cell
type
could
lead
increas
mab
halflif
vivo
also
stronger
vaccinelik
effect
inde
fcrn
crosslink
apc
multival
ic
shown
entail
stronger
humor
cellular
adapt
respons
certain
infect
set
addit
enhanc
fcrn
function
broadli
neutral
mab
improv
protect
shiv
infect
macaqu
igg
isotyp
display
equival
effector
function
anoth
possibl
may
resid
either
antibodi
subclass
select
subclass
switch
via
genet
engin
human
antivir
mab
studi
far
display
strong
affin
fcgr
complement
howev
recent
data
suggest
human
igg
subtyp
may
exert
stronger
antivir
effect
least
certain
condit
thu
antibodi
hiv
gag
suggest
contribut
immun
control
hiv
infect
broaden
enhanc
function
igg
antibodi
moreov
increas
vaccin
efficaci
decreas
risk
infect
one
two
clinic
trial
correl
develop
highli
function
antihiv
clearli
work
still
need
establish
alter
antibodi
effector
function
isotyp
select
may
exploit
enhanc
induc
mabinduc
antivir
vaccinelik
effect
task
complic
differ
fcgr
express
variou
level
differ
apc
show
function
polymorph
support
possibl
fcgriia
polymorph
repres
genet
risk
factor
latent
epsteinbarr
viru
ebv
infect
express
oncogen
latenc
protein
furthermor
fcgriia
fcgriiia
polymorph
associ
variat
hiv
diseas
progress
progress
hiv
infect
associ
decreas
express
fcgriia
addit
fcgriic
polymorph
shown
impact
vaccin
protect
infect
cell
target
antivir
mab
target
viral
antigen
express
infect
cell
rather
virion
might
reward
term
induct
vaccinelik
effect
approach
would
mainli
concern
envelop
virus
display
viral
receptorbind
protein
surfac
virusproduc
cell
fact
cellular
ic
crucial
induc
longlast
immun
frcase
neutral
mab
see
substanti
idea
addit
hivinfect
cell
stronger
induc
innat
immun
cellfre
virion
hcvinfect
hepatocyt
report
affect
dc
matur
subsequ
activ
nk
cell
cell
wherea
free
viru
could
indic
infect
cell
may
stronger
induc
immun
compar
virion
import
establish
whether
antigen
potenti
infect
cell
enhanc
upon
opson
antivir
mab
case
frcase
past
year
mount
evid
reveal
antivir
mab
may
use
recruit
endogen
immun
system
infect
organ
induc
longlast
vaccinelik
effect
major
issu
translat
observ
human
applic
benefit
patient
societi
see
outstand
question
much
research
toward
aim
howev
still
necessari
particular
essenti
identifi
molecular
cellular
mechan
wherebi
viral
cellular
ic
form
immunotherapi
induc
protect
immun
determin
best
mean
exploit
therapeut
also
like
improv
effector
function
antivir
mab
andor
combin
therapeut
necessari
achiev
steril
immun
infect
agent
least
longterm
contain
cellular
type
molecular
effector
involv
induct
vaccinelik
effect
antivir
monoclon
antibodi
mab
fcdepend
effector
function
isar
need
involv
induct
vaccinelik
effect
genet
engin
improv
vaccinelik
effect
antivir
mab
combin
therapi
improv
vaccinelik
effect
antivir
mab
mab
therapi
commenc
mab
therapi
combin
therapi
best
approach
counteract
immunosuppress
respons
best
target
antivir
mab
viru
andor
infect
cell
fcgr
polymorph
use
predict
factor
vaccinelik
effect
antivir
mab
program
refer
also
support
work
grate
dr
robbin
critic
read
manuscript
